Career history of Lee B. Bussey
Former positions of Lee B. Bussey
| Companies | Position | Start | End |
|---|---|---|---|
Valentis, Inc.
 Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Corporate Officer/Principal | 01/01/1994 | 01/01/2006 |
| Georgia State University | Corporate Officer/Principal | - | - |
| University of Illinois | Corporate Officer/Principal | - | - |
Juvaris BioTherapeutics, Inc.
 Juvaris BioTherapeutics, Inc. BiotechnologyHealth Technology Juvaris BioTherapeutics, Inc. develops novel, adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer. The company was founded by Martin D. Cleary, Jeff Fairman and Steven W. Dow in February 2003 and is headquartered in Burlingame, CA. | Corporate Officer/Principal | - | - |
Training of Lee B. Bussey
| University of California, Davis | Doctorate Degree |
Statistics
International
| United States | 6 |
Operational
| Corporate Officer/Principal | 4 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Consumer Services | 4 |
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Juvaris BioTherapeutics, Inc.
Juvaris BioTherapeutics, Inc. BiotechnologyHealth Technology Juvaris BioTherapeutics, Inc. develops novel, adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer. The company was founded by Martin D. Cleary, Jeff Fairman and Steven W. Dow in February 2003 and is headquartered in Burlingame, CA. | Health Technology |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Health Technology |
- Stock Market
- Insiders
- Lee B. Bussey
- Experience
